Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$691M |
| 2 |
Mercado Libre
MELI
|
+$341M |
| 3 |
Spotify
SPOT
|
+$335M |
| 4 |
WIX.com
WIX
|
+$315M |
| 5 |
Roblox
RBLX
|
+$233M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$334M |
| 2 |
CBRE Group
CBRE
|
+$310M |
| 3 |
Amazon
AMZN
|
+$302M |
| 4 |
NVIDIA
NVDA
|
+$296M |
| 5 |
Trade Desk
TTD
|
+$255M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 27.49% |
| 2 | Healthcare | 25.5% |
| 3 | Technology | 17.13% |
| 4 | Communication Services | 10.66% |
| 5 | Financials | 7.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
301
Bristol-Myers Squibb
BMY
$132B
| $38K | ﹤0.01% |
488
+25
| +5% | +$1.9K |
|
|
NEWR
302
DELISTED
New Relic, Inc.
NEWR
| $37K | ﹤0.01% |
733
| – | – |
|
303
Halozyme
HALO
$12.2B
| $36K | ﹤0.01% |
815
+36
| +5% | +$1.56K |
|
|
P
304
Everpure Inc
P
$29.9B
| $34K | ﹤0.01% |
1,335
| – | – |
|
305
UnitedHealth
UNH
$370B
| $34K | ﹤0.01% |
67
| – | – |
|
306
Amkor Technology
AMKR
$13.7B
| $33K | ﹤0.01% |
1,976
+211
| +12% | +$4.01K |
|
307
Amdocs
DOX
$6.22B
| $32K | ﹤0.01% |
386
+21
| +6% | +$1.73K |
|
308
Inspire Medical Systems
INSP
$1.74B
| $32K | ﹤0.01% |
173
+19
| +12% | +$3.79K |
|
309
Costco
COST
$420B
| $30K | ﹤0.01% |
63
| – | – |
|
310
Regeneron Pharmaceuticals
REGN
$80.8B
| $30K | ﹤0.01% |
50
+4
| +9% | +$2.6K |
|
311
Tractor Supply
TSCO
$18B
| $30K | ﹤0.01% |
775
+95
| +14% | +$3.86K |
|
|
EH
312
EHang Holdings
EH
$435M
| $29K | ﹤0.01% |
3,105
+155
| +5% | +$1.46K |
|
313
ON Semiconductor
ON
$31.6B
| $29K | ﹤0.01% |
575
+75
| +15% | +$4.18K |
|
314
Humana
HUM
$46.2B
| $28K | ﹤0.01% |
60
+4
| +7% | +$1.78K |
|
315
W.W. Grainger
GWW
$60.2B
| $27K | ﹤0.01% |
60
+1
| +2% | +$486 |
|
|
GBT
316
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $27K | ﹤0.01% |
835
| – | – |
|
317
AstraZeneca
AZN
$250B
| $26K | ﹤0.01% |
200
| – | – |
|
318
Exelixis
EXEL
$13.4B
| $26K | ﹤0.01% |
1,230
+30
| +3% | +$618 |
|
319
Jazz Pharmaceuticals
JAZZ
$16.7B
| $26K | ﹤0.01% |
168
+3
| +2% | +$462 |
|
320
Pfizer
PFE
$153B
| $26K | ﹤0.01% |
500
| – | – |
|
321
Box
BOX
$4.6B
| $25K | ﹤0.01% |
979
| – | – |
|
322
Pool Corp
POOL
$7.5B
| $25K | ﹤0.01% |
70
| – | – |
|
323
Coherent
COHR
$74.2B
| $24K | ﹤0.01% |
477
+2
| +0.4% | +$122 |
|
324
Medifast
MED
$141M
| $24K | ﹤0.01% |
133
+13
| +11% | +$2.33K |
|
325
Monolithic Power Systems
MPWR
$68.9B
| $24K | ﹤0.01% |
63
| – | – |
|
Similar funds
Baillie Gifford & Co's Q2 2022 Portfolio in Review
As of Q2 2022, Baillie Gifford & Co held 526 positions worth $97.5B, down 32% from $143B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Baillie Gifford & Co's Q2 2022 filing shows 28 new, 112 increased, 187 reduced and 33 closed positions. Its largest new stake was Hershey: 94,977 shares worth $20.4M. The largest sale was Tesla, an estimated $334M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 27% of assets, down from 28% a quarter earlier, followed by Healthcare and Technology.
- Baillie Gifford & Co's largest Q2 2022 buy was Hershey: 94,977 shares worth $20.4M.
- Baillie Gifford & Co added most to Royalty Pharma in Q2 2022, an estimated $691M increase.
- Baillie Gifford & Co's biggest Q2 2022 reduction was Tesla, cutting an estimated $334M.
- Baillie Gifford & Co fully exited iShares Silver Trust in Q2 2022, selling an estimated $21.2M.
- Baillie Gifford & Co's ten largest holdings make up 36% of its $97.5B portfolio in Q2 2022.
- Baillie Gifford & Co opened 28 new positions and closed 33 in Q2 2022.
- Baillie Gifford & Co's portfolio value fell 32% quarter-over-quarter to $97.5B.
Based on Baillie Gifford & Co's 13F filing for Q2 2022, filed 8 Aug 2022.